Home / Health / Panama trial begins for revolutionary knee cartilage implant
Panama trial begins for revolutionary knee cartilage implant
17 Aug
Summary
- Chondrograft knee implant trial begins in Panama.
- The implant aims to promote cartilage regeneration.
- Device has breakthrough status from the FDA.
Nanochon has secured approval from Panama's Ministry of Health to initiate its first-in-human trial for Chondrograft, an implant engineered to treat articular cartilage defects in the knee.
The clinical trial, set to take place at The Panama Clinic in Panama City, will assess the safety and efficacy of Chondrograft in patients between 22 and 60 years old suffering from specific knee cartilage lesions.
This significant milestone for Nanochon follows its designation as a breakthrough device by the US Food and Drug Administration. The company chose Panama for its efficient regulatory processes and robust clinical infrastructure.
Additionally, Nanochon has received permission from Health Canada to conduct a study in the country, with patient recruitment already underway in Ontario, underscoring the global interest in this novel cartilage repair technology.
